Published TCIMAIL newest issue No.198
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 357336-20-0 | Product Number: B6660
Brivaracetam
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- (2S)-2-[(4R)-2-Oxo-4-propyl-1-pyrrolidinyl]butanamide
- (S)-2-[(R)-2-Oxo-4-propylpyrrolidin-1-yl]butanamide
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 25MG |
€390.00
|
Contact Us | ≥40 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | B6660 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__1H__2__0N__2O__2 = 212.29 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| CAS RN | 357336-20-0 |
| Reaxys Registry Number | 9629290 |
| MDL Number | MFCD13152385 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Volumetric Analysis) | min. 98.0 % |
| Melting point | 75.0 to 79.0 °C |
| Specific rotation | -56.0 to -62.0 deg(C=1, methanol) |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 77 °C |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H336 : May cause drowsiness or dizziness. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P261 : Avoid breathing dust. P271 : Use only outdoors or in a well-ventilated area. P304 + P340 + P312 : IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/doctor if you feel unwell. P403 + P233 : Store in a well-ventilated place. Keep container tightly closed. P405 : Store locked up. |
Related Laws:
Transport Information:
Application
Brivaracetam: A Selective and High Affinity SV2A Ligand
Brivaracetam (UCB 34714) is chemically related to levetiracetam [L0234]. Synaptic vesicle glycoprotein 2A (SV2A) is a synaptic vesicle protein that regulates potential-dependent neurotransmitter release. Brivaracetam has a selective binding affinity for SV2A that is 15 to 30 times higher than that of levetiracetam, which may contribute to its anticonvulsant activity. (The product is for research use only.)
References
- Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A
- Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties
- Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy
- Synthetic Approaches toward the Synthesis of Brivaracetam: An Antiepileptic Drug (a review)
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.